Bevacizumab biosimilar (Celltrion)

静脉注射（IV）长期是抗体药物的默认给药方式，但它占用输液椅、依赖医院场景、患者依从性受限。皮下注射（SC）把给药从医院小时级压缩到居家分钟级。在 2025 年全球抗体销售 TOP50 中，已有 30 款具备皮下给药能力（占 60%），高浓度处方把注射体积压到 1–2 mL、把时间压到几分钟。真正决定这场迁移能走多远的，是蛋白自身的溶解度与聚集倾向。00 给药途径：皮下已成主战场 TOP50 里 30 款带 SC 能力，其中 11 款做成 IV/SC 双剂型——同一分子、两条路径，既保住原有 IV 基本盘，又用居家 SC 抢依从性与生命周期。01 皮下递送技术谱系 技术分两派：酶解法（ENHANZE® 由 Halozyme 提供，Keytruda 用 Merck 自研透明质酸酶）靠降解皮下透明质酸扩容；高浓度处方派不靠酶，靠制剂把体积压下去。前者快、后者自主可控。02 高浓度：浓度阶梯 皮下浓度已普遍站上 100–200 mg/mL：Belimumab 达 200、Keytruda Qlex 165。浓度越高，单次注射体积越小，患者体验越好——但物理约束同步收紧。03 溶解性：被误解的底层约束 治疗性抗体均为亲水糖蛋白、水溶性好；脂溶性（LogP）是 small-molecule 渗透属性，对 150 kDa 生物大分子不适用。ADC 因细胞毒载荷亲脂，标注水溶性（载荷亲脂），但其载荷脂溶性不改变整体水针体系。高浓度皮下制剂的核心物理瓶颈，是蛋白本身的溶解度与聚集倾向，而非脂水分配。04 TOP50 总榜 名次 药物（商品名/通用名） 销售额亿$ 增速 途径 1 Keytruda /pembrolizumab 316.8 7.5%IV/SC 2 Dupixent /dupilumab 177.36 20.2%SC 3 Skyrizi /risankizumab 175.62 49.9%SC 4 Darzalex /daratumumab 143.51 23%IV/SC 5 Opdivo /nivolumab 100.49 8%IV/SC 6 Ocrevus /ocrelizumab 84.36 3.9%IV 7 Cosentyx /secukinumab 66.68 8.6%SC 8 Stelara /ustekinumab 60.78 -41.3%IV/SC 9 Imfinzi /durvalumab 60.63 28.5%IV 10 Entyvio /vedolizumab 55.6 5.8%IV/SC 11 Hemlibra /emicizumab 52.3 15%SC 12 Tremfya /guselkumab 51.55 40.5%SC 13 Enhertu /trastuzumab deruxtecan 49.82 40%IV 14 Vabysmo /faricimab 49.36 6.1%IVT 15 Ultomiris /ravulizumab 47.18 19%IV/SC 16 Humira /adalimumab 45.4 -49.5%SC 17 Kesimpta /ofatumumab 44.26 37.3%SC 18 Prolia /denosumab 44.14 1%SC 19 Tecentriq /atezolizumab 39.2 -1.4%IV 20 Orencia /abatacept 37.05 0.6%IV/SC 21 Taltz /ixekizumab 35.62 12%SC 22 Eylea /aflibercept 35 -48%IVT 23 Xolair /omalizumab 33.8 32%SC 24 Perjeta /pertuzumab 32.6 -3.2%IV 25 Repatha /evolocumab 30.16 36%SC 26 Yervoy /ipilimumab 29 14.6%IV 27 Actemra /tocilizumab 27.2 -2%IV/SC 28 Phesgo /pertuzumab+trastuzumab (SC) 26.9 70%SC 29 Tezspire /tezepelumab 25.8 52%SC 30 Nucala /mepolizumab 25.5 15%SC 31 Padcev /enfortumab vedotin 25.4 22%IV 32 Bimekizumab /bimekizumab 24 100%SC 33 Kadcyla /ado-trastuzumab emtansine 23.3 7%IV 34 Benlysta /belimumab 22.5 22%IV/SC 35 Enbrel /etanercept 22.26 -33%SC 36 Evenity /romosozumab 21 34%SC 37 Xgeva /denosumab 20.84 -6%SC 38 Fasenra /benralizumab 19.81 16%SC 39 Tysabri /natalizumab 18.5 -3%IV 40 Soliris /eculizumab 18.37 -16%IV 41 Adcetris /brentuximab vedotin 17.79 -17%IV 42 Polivy /polatuzumab vedotin 16.9 39%IV 43 Blincyto /blinatumomab 15.59 28%IV 44 Trodelvy /sacituzumab govitecan 13.97 6%IV 45 Rituxan /rituximab 13.8 -13%IV/SC 46 Opdualag /nivolumab+relatlimab 11.85 27%IV 47 Vectibix /cetuximab 11.75 12%IV 48 Herceptin /trastuzumab 11.3 -11%IV/SC 49 Gazyva /obinutuzumab 10.8 15%IV 50 Avastin /bevacizumab 10.7 -10%IV 增速：红为同比正增长、绿为负增长（单位货币折算美元）。05 皮下递送明细（SC / IV·SC 共 30 款） 商品名 皮下浓度 递送技术Keytruda 165 mg/mLMerck 自研透明质酸酶(berahyaluronidase)Dupixent 150 mg/mL高浓度处方·无酶Skyrizi 150 mg/mL高浓度处方·无酶Darzalex 120 mg/mLENHANZE®(Halozyme rHuPH20)Opdivo 120 mg/mLENHANZE®(Halozyme rHuPH20)Cosentyx 150 mg/mL高浓度处方·无酶Stelara 90 mg/mL标准浓度·无酶Entyvio 160 mg/mL高浓度处方·无酶Hemlibra 30–150 mg/mL高浓度处方·无酶Tremfya 100 mg/mL高浓度处方·无酶Ultomiris 70 mg/mL标准浓度·无酶Humira 50 mg/mL标准浓度·无酶Kesimpta 50 mg/mL标准浓度·无酶Prolia 60 mg/mL标准浓度·无酶Orencia 125 mg/mL高浓度处方·无酶Taltz 80 mg/mL标准浓度·无酶Xolair 150 mg/mL高浓度处方·无酶Repatha 140 mg/mL高浓度处方·无酶Actemra 162 mg/mL高浓度处方·无酶Phesgo 80+40 mg/mLENHANZE®(Halozyme rHuPH20)Tezspire ≈110 mg/mL高浓度处方·无酶Nucala 100 mg/mL高浓度处方·无酶Bimekizumab 160 mg/mL高浓度处方·无酶Benlysta 200 mg/mL高浓度处方·无酶Enbrel 50 mg/mL标准浓度·无酶Evenity ≈90 mg/mL标准浓度·无酶Xgeva 70 mg/mL标准浓度·无酶Fasenra 30 mg/mL标准浓度·无酶Rituxan 120 mg/mLENHANZE®(Halozyme rHuPH20)Herceptin 120 mg/mLENHANZE®(Halozyme rHuPH20) 本表 30 款均为水溶性（含 ADC 载荷亲脂情形不出现在 SC 剂型）。06 受类似药压力：原研的护城河，也是类似药企的机会 首个 K 药类似药 FYB206（Formycon / Zydus）的 BLA 已于 2026-10-13 获 FDA 受理进入审评，预计 2027 Q3 出结果；但截至发稿它仍处审评中、尚未在任何国家/地区获批，上市还须过批准与专利两关。IQVIA Institute 测算，2025–2034 年美国将有 118 款生物药失去独占权，销售敞口约 2320 亿美元（232 Bn）；但其中仅 12 款目前有生物类似药在研，余下 106 款（约 90%）尚无管线，被称为 biosimilar void（类似药空白）。TOP50 里已有 16 款处于类似药压境——其中 12 款已部署皮下盾，仅 4 款裸奔。同一场浪潮，对原研是压力，对类似药企却是机会。A 档 · 已被实质侵蚀（增速转负，数据自证） 名次 商品名 销售额亿$ 增速 类似药状态 8 Stelara 60.78 -41.3 IV/SC Wezlana 2023 获批、2025 上市 16 Humira 45.4 -49.5 SC 美国类似药 2023 上市，2025 全球−49.5% 19 Tecentriq 39.2 -1.4 IV 欧盟类似药在研 22 Eylea 35 -48 IVT Yesafili / Yuflyma 2024–25 上市 35 Enbrel 22.26 -33 SC Erelzi 获 FDA，美国仍受专利挡 39 Tysabri 18.5 -3 IV 类似药进展有限 40 Soliris 18.37 -16 IV Epysqli / Bkemv 获批，主战场已转 Ultomiris(SC) 45 Rituxan 13.8 -13 IV/SC 多个类似药在售 48 Herceptin 11.3 -11 IV/SC 多个类似药在售 50 Avastin 10.7 -10 IV 多个类似药在售B 档 · 压力在门口（首类似药已受理 / 即将上市） 名次 商品名 销售额亿$ 途径 类似药状态 1 Keytruda 316.8 7.5 IV/SC FYB206 BLA 已受理（本文主角），2027 Q3 决定 5 Opdivo 100.49 8 IV/SC 类似药在研，LOE≈2028 18 Prolia 44.14 1 SC 类似药 Jubbonti / Wyost 2025 上市 23 Xolair 33.8 32 SC 欧盟类似药 2024 获批，美国尚早 27 Actemra 27.2 -2 IV/SC Tofidence / Tyenne 2023 获批 37 Xgeva 20.84 -6 SC 类似药 Jubbonti / Wyost 2025 上市 对原研药企，类似药是生命周期倒计时器：在九成分子尚无管线的空白期里，皮下高浓度是最现实的护城河——把 IV 升级为 SC 双剂型，能在类似药真正到来前多守几年患者与现金流。对类似药企，这更是 best-in-class 的机会：当全行业仅 12 款在研、多数分子连管线都没有，同质化低价 copy 只会陷进原研的专利丛林；真正的突破口，是用新技术 + 新知识产权重构给药——谁能以自有专利保护的新型水相高浓度递送平台，把产品做成带差异化 IP 护城河的 biobetter，谁就握有定价权与可防御的窗口。已有先例：Celltrion 的 Remsima SC 拿下欧洲英夫利昔约 71% 份额，Zymfentra 上市 5 个月获美 75% 医保覆盖；Alteogen 的透明质酸酶平台 ALT-B4 凭自有 IP 授权给 Sanofi（Dupixent 高浓度 SC）等。最暴露的仍是纯 IV / 玻璃体内的裸奔药——Avastin、Tecentriq、Tysabri、Eylea，原研难守、类似药也缺差异化抓手。而高浓度皮下递送本身正是那道最难的技术门槛：能在一个自有知识产权保护的完全水相体系中负载、保持蛋白水溶性并叠加长效缓释者，才握着这张空白窗口里 best-in-class 的主动权。07 下一个战场：TCE / ADC / 双抗的皮下高浓度刚需 经典单抗（Humira、Stelara、Keytruda Qlex 等）已把皮下高浓度跑到 100–200 mg/mL，常规打法趋于成熟。真正的下一程，是模态更复杂的生物大分子——它们恰恰最怕反复去医院 IV，却最难做成高浓度皮下。 模态 皮下高浓度成熟度 核心痛点双抗 进行中 emicizumab / Hemlibra 已证 SC 可行；不对称结构＋高频给药使高浓度皮下仍复杂，SC 经淋巴慢吸收可缓解细胞因子释放综合征（CRS）TCE（T 细胞衔接器） 演进中 epcoritamab 已 SC、blinatumomab 类由持续 IV 输注转向 SC；多数仍 IV，高浓度皮下稀缺ADC 基本未解 获批 19 款全为 IV；载荷亲脂致聚集倾向上升、可注射性下降，连接子-载荷皮下不稳定，高浓度 SC ADC 几乎无解 三类里 ADC 最难：截至 2025 年底全球获批的 19 款 ADC 全部为 IV 给药；细胞毒载荷（如 MMAE、MMAF、PBD 类）亲脂，浓度抬升时蛋白-蛋白相互作用增强、聚集倾向与溶液非理想行为同步上升，高浓度皮下 ADC 至今基本无解。TCE 与双抗虽已有皮下先例（epcoritamab 已 SC、emicizumab / Hemlibra 是 SC 成功范本），但高频给药与不对称结构带来的处方复杂度，仍使高浓度皮下远未普及。对这三类增长引擎而言，皮下高浓度不是锦上添花，而是能否把给药从医院搬到居家的分水岭——这也正是新一代高浓度皮下递送技术（含可在完全水相中负载、并叠加缓释的凝聚体路线）真正的用武之地。08 作者点评 皮下高浓度不是换根针头的小事，而是大药生命周期管理的标准动作：专利悬崖逼近时，把 IV 升级为 SC 双剂型，能延长商业化窗口、提升患者黏性。但技术门槛不在装置，在处方——谁能在 150–200 mg/mL 下把聚集与稳定性同时压住，谁就握着下一代递送的主动权。往更前沿看，高浓度皮下给药仍有两道命题待解：一是浓度继续抬升时，注射体积与局部耐受性的矛盾；二是如何把给药频率从每周、每两周进一步拉长。凝聚体（生物分子凝聚体，由液-液相分离形成的液滴）作为一种新兴递送策略正受到关注——它能在完全水相体系中负载抗体，既保持蛋白水溶性、免去冻干与复溶，又借相分离网络实现长效缓释，延长给药间隔。对 200 mg/mL 这一浓度量级而言，能在不牺牲溶解度与稳定性的前提下叠加缓释，是把皮下高浓度从给药便利推向给药范式的关键一步。 数据来源：各公司 2024 / 2025 财年公开年报与财报（销售额折算美元，增速为同比）；给药途径、皮下浓度、递送技术取自公开说明书与研发披露；部分早期或估算值标估。利益相关声明：作者从事凝聚体高浓度抗体皮下递送与长效缓释技术研发，文中相关技术路线讨论仅代表个人科学研判，不涉及任何企业产品或商业合作，亦不构成投资建议。

New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitis Late-breaking analysis shows significantly higher rates of clinical remission and improved endoscopic outcomes with subcutaneous versus intravenous infliximab in patients with ileum-dominant Crohn's disease Oct. 11, 2026 -- Celltrion USA, Inc. today announced that two analyses evaluating ZYMFENTRA® (infliximab-dyyb) will be presented in oral presentations on Oct. 13 and 14 at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee. The data include a late-breaking pooled and propensity score-matched analysis comparing subcutaneous (SC) and intravenous (IV) infliximab in patients with ileum-dominant Crohn's disease, as well as a post hoc analysis from the Phase 3 LIBERTY-CD and LIBERTY-UC studies assessing the impact of prior anti-drug antibody (ADA) status on clinical outcomes following SC infliximab 240 mg initiation after interruption of IV infliximab treatment. [1,2] "People living with inflammatory bowel disease (IBD) can have varied disease characteristics, presentations, and treatment histories that may shape a unique care pathway, and clinicians need evidence that reflects the range of patients they see," said Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. "We're pleased to share new analyses at ACG that provide additional information about subcutaneous infliximab in Crohn's disease and ulcerative colitis and reflect Celltrion's commitment to advancing clinically meaningful research for the IBD community." Presentation Details Both analyses will be presented by Marla Dubinsky, M.D., Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine, Mount Sinai, New York. Post Hoc Analysis of LIBERTY-CD and -UC Studies Following an IV Infliximab Treatment Interruption Date: Tuesday, Oct. 13, from 2:45-2:55 p.m. CT Room: Karl F. Dean Grand Ballroom A, Level 4 Abstract Title: "Impact of Prior Anti-drug Antibody Status on Clinical Outcomes Following Subcutaneous Infliximab Initiation After Intravenous Infliximab Interruption: A Post Hoc Analysis of LIBERTY-CD and -UC Studies" Session: Plenary Session 3A: IBD Presentation: 40 A separate post hoc analysis evaluated efficacy, serum infliximab concentrations, and immunogenicity among patients from the placebo arms of the Phase 3 LIBERTY-CD and LIBERTY-UC studies who initiated SC infliximab 240 mg every two weeks following an interruption in IV infliximab treatment. Patients were assessed according to whether anti-drug antibodies (ADAs) had been detected before they began SC infliximab.[2] Among patients who initiated SC infliximab 240 mg, 72.5% (37 of 51) of patients with Crohn's disease and 92.2% (71 of 77) of patients with ulcerative colitis had prior ADA positivity. The median interval between the last IV infliximab infusion and initiation of SC infliximab was 16 weeks in ADA-positive and ADA-negative patients in both the Crohn's disease and ulcerative colitis groups.[2] Across Crohn's disease and ulcerative colitis populations, the analysis found clinical outcomes were generally similar regardless of whether patients had ADAs before starting SC infliximab, with clinical response in Crohn's disease and partial clinical response in ulcerative colitis observed by 8±2 weeks and sustained through 78 to 80 weeks. Serum infliximab concentrations increased after initiation of SC infliximab and were generally comparable over time across ADA-status groups. Levels of fecal calprotectin and C-reactive protein decreased at the first assessment after treatment began and remained lower through the final assessment. ADA positivity declined among patients with pre-existing ADAs, while new ADA development was uncommon in patients without prior ADAs. "Anti-drug antibodies to intravenous infliximab can compromise infliximab reinitiation after treatment interruption. Data on subcutaneous infliximab initiation after a drug holiday are limited, particularly regarding the impact of prior ADA status on clinical outcomes," said Marla Dubinsky, M.D., Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine, Mount Sinai, New York. "These post hoc findings suggest that prior ADA status did not appear to compromise clinical outcomes after initiating subcutaneous infliximab following drug holiday after intravenous infliximab induction." Date: Wednesday, Oct. 14, from 9:30-9:40 a.m. CT. Late-Breaking Abstract Title: "Comparative Efficacy of Subcutaneous Versus Intravenous Infliximab in Ileum-Dominant Crohn's Disease: A Pooled Analysis and Propensity Score-Matched Analysis of Infliximab Registrational Studies" Session: Plenary Session 4B: Liver, Esophagus, CRC, IBD Presentation: 72 The late-breaking abstract reports a pooled analysis of individual patient data from four infliximab registrational studies. The analysis included patients with ileal or ileocolonic Crohn's disease who received standard maintenance treatment with SC infliximab 120 mg every two weeks or IV infliximab 5 mg/kg every eight weeks. Of 884 patients across the studies, 200 met the eligibility criteria; a 1:1 propensity score-matched analysis included 70 patients in each treatment group.[1]In the matched population at Week 54, patients receiving SC infliximab had higher rates of clinical remission, endoscopic response, and endoscopic remission than those receiving IV infliximab:[1] Clinical remission: 71.4% vs. 51.4% (P = 0.023) Endoscopic response: 65.7% vs. 27.1% (P < 0.001) Endoscopic remission: 41.4% vs. 17.1% (P = 0.003) The analysis also found that, in both treatment groups, endoscopic responders had significantly higher serum infliximab concentrations than nonresponders. ZYMFENTRA® (infliximab-dyyb) is a prescription medicine used as an injection under the skin (subcutaneous injection) by adults for the maintenance treatment of moderately-to-severely active ulcerative colitis following treatment with an infliximab product given by intravenous infusion (IV), Moderately-to-severely active Crohn's disease following treatment with an infliximab product given by intravenous infusion (IV). ZYMFENTRA blocks the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be overproduced in response to certain diseases and cause the immune system to attack normal, healthy parts of the body. ZYMFENTRA was approved by the FDA through the Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a "stand-alone" BLA). ZYMFENTRA is considered a new biologic with a first-approved subcutaneous administration form and thus will be under patent protection for its dosage form by 2037 and for its route of administration by 2040. The American College of Gastroenterology (ACG) is a recognized leader in educating GI professionals and the general public about digestive disorders. ACG's mission is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation, and advocacy in the areas of scientific investigation, education, prevention, and treatment. The 2026 ACG Annual Scientific Meeting & Postgraduate Course will convene in Nashville, Tennessee, from October 9 to 14, 2026. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, endocrinology and ophthalmology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), EGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (ustekinumab-stba), STOBOCLO ® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), OMLYCLO® (omalizumab-igec), and EYDENZELT® (aflibercept-boav), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. The content above comes from the network. if any infringement, please contact us to modify.